BC Week In Review | Jan 20, 2017
Clinical News

DMT210: Ph II DMT210-003 started

Dermata began the double-blind, vehicle-controlled, U.S. Phase II DMT210-003 trial to evaluate DMT210 5% topical gel twice daily for 12 weeks in about 104 patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see...
BC Week In Review | Dec 9, 2016
Clinical News

DMT210: Ph II DMT210-02 started

Dermata began the double-blind, vehicle-controlled, U.S. Phase II DMT210-002 trial to evaluate twice-daily topical DMT210 gel for 28 days in 25 patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27,...
BC Week In Review | Oct 3, 2016
Clinical News

SIG990: Phase I data

Top-line data from an open-label, U.S. Phase I trial in patients with acne rosacea showed that twice-daily topical DMT210 for 28 days was well tolerated and reduced erythema and lesion counts. This year, Dermata plans...
BC Week In Review | May 23, 2016
Clinical News

SIG990: Phase I started

Dermata began an open-label, U.S. Phase I trial to evaluate twice-daily topical DMT210 for 28 days in 10 patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27, 2015). Dermata Therapeutics...
BC Week In Review | Apr 27, 2015
Company News

Signum Dermalogix, Dermata Therapeutics deal

Signum granted Dermata exclusive, worldwide rights to SIG990 . An IND for the rosacea candidate has been cleared by the FDA. Dermata is responsible for clinical development of the topical anti-inflammatory small molecule analog of isoprenylcysteine...
BC Week In Review | Feb 18, 2013
Company News

Brickell Biotech, Signum Dermatologix Inc. deal

Last December, Brickell terminated an April 2012 deal with Signum (formerly Argyle Therapeutics Inc. ) granting Brickell exclusive, worldwide rights to develop and commercialize SIG990 for dermatology indications. According to Signum, Brickell exited the deal after...
BioCentury | Feb 18, 2013
Emerging Company Profile

Signum: Rosacea double play

Therapies on the market or in development for rosacea treat either the symptomatic flushing or the inflammatory skin lesions. Signum Dermalogix Inc. 's lead small molecule isoprenylcysteine analog could treat both aspects of rosacea by...
BC Week In Review | Apr 23, 2012
Company News

Argyle Therapeutics, Brickell Biotech Inc deal

Argyle granted Brickell exclusive, worldwide rights to develop and commercialize SIG990 for dermatology indications. Argyle is eligible for milestones and royalties. The topical anti-inflammatory small molecule is in preclinical testing to treat rosacea. Details were...
Items per page:
1 - 8 of 8